Tiziana Life Sciences (NASDAQ: $TLSA) is a biotech firm pushing the boundaries in the discovery and development of novel molecules to treat human diseases. On Tuesday, February 11, 2025, it announced the results of an investigational therapy to treat Alzheimer’s disease.
Details Of The Trial
On June 26, 2024, Tiziana announced it had received FDA approval under the Expanded Access IND to dose its first patient with moderate Alzheimer’s with an investigational intranasal foralumab. At the time, Gabriele Cerrone, Executive Chairman and founder of Tiziana Life Sciences, stated that additional FDA clearance allowed the company to “study intranasal foralumab in patients with moderate Alzheimer’s Disease who do not qualify for approved therapies.”
Tiziana Life Sciences Releases Results Of Investigational Therapy
According to a Tuesday, February 11, 2025 announcement, Tiziana revealed that the investigational therapy was featured on a prominent news channel. According to the news report, the patient, named Joe, was diagnosed with Alzheimer’s in 2019; the family is hopeful.
According to the news channel, Doctors at Brigham and Women’s want to test foralumab on a larger group of Alzheimer’s patients, with clinical trials set to begin as early as next month. Those who want to enroll can find more information here.
Commenting on the news report, Dr. Howard Weiner, Co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham healthcare system, stated that intranasal foralumab was “potentially slowing disease progression and improving cognitive function. The recent coverage in the News underscores the growing recognition of Foralumab’s promise in the field of neurodegenerative diseases.”
What Is Foralumab?
Foralumab is a molecule designed to reduce inflammation in the brain, which is a common feature in many neurologic diseases. It has been shown to stimulate T regulatory cells when administered intranasally.
According to the Tiziana announcement, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate-sized Expanded Access (EA) Program. It states that they have seen improvement or stabilization of the disease within 6 months. Tiziana stated that the FDA had recently approved an additional 20 patients to be enrolled in this program.
The company stated that intranasal foralumab was also being studied in Phase 2a, a randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis.
Tiziana Market performance
Tiziana (TLSA) is up 5.71% year to date, and 42.31% in the past 12 months, beating the S&P 500, which is up 21.47% in the past year. Its current price is below its 50-, and 200-day moving verages of $0.7962, and $0.8992, respectively. According to an analysis by Fintel, the stock could gain 309.09% to $3.06 per share by July 2025.
Is Tiziana (TLSA) A Buy
The early success of Tiziana’s Alzheimer’s treatment will place it squarely in the sights of investors looking for the next obesity-lie market opportunity. According to a January 10, 2025 report by Bloomberg, major firms like Eli Lilly and Biogen have spent billions on potential treatments.
The report states that any breakthroughs in trials of drug approvals could positively impact share prices as investors price in potential sales in a market of $13 billion by 2030.
One advantage that Tiziana has over major firms is its small cap. With the first trial showing promise, it presents an opportunity for potentially massive returns for early investors. Consequently, Tiziana (TLSA) could potentially be a better investment opportunity than mature firms’ stocks.
Click Here For Updates on TLSA – It’s FREE to Sign Up for Text Message Notifications!
Disclaimer: This website provides information about cryptocurrency and stock market investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for educational and informational purposes only. The owner of this website is not a registered investment advisor and does not offer investment advice. You, the reader / viewer, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. We have been compensated ten thousand dollars electronically via bank wire by One Eyed Jack Enterprises LLC for an advertising / marketing campaign for Tiziana Life Sciences Ltd. (NASDAQ: $TLSA) beginning on 2/13/2025 and ending on 2/20/2025. DEXWireNews may receive additional campaigns in the future by One Eyed Jack Enterprises LLC to distribute media for Tiziana Life Sciences Ltd. (NASDAQ: $TLSA).